Over the years, several RET/PTC rearrangements have been reported in thyroid carcinoma, all characterized by the fusion of the tyrosine kinase domain of the receptor with a ubiquitous driver gene that allows the illegitimate kinase expression in cells that commonly do not express it (i.e., follicular cells) (Figure 2A). The gene discussed is RET; the disease is thyroid gland carcinoma.